Helen Kim Cho, PhD, is an Associate Research Fellow in the Vaccine Immunotherapeutics group. She currently holds the Research and Scientific Lead roles for the Vaccine Based Immunotherapy Regimen program which entered the clinic early this year for the treatment of prostate cancer and the Oncolytic Based Immunotherapy Regimen which is in preclinical development. Dr. Cho is a member of the Pfizer-Western Oncolytic Joint Development Committee and is the point of contact for scientific exchange between Vaccine Immunotherapeutics and Western Oncolytics. Additionally, she is a subject matter expert for developing strategies for combining immuno-oncology assets and leads a group of Immunopharmacology colleagues in testing of novel combinations in preclinical models. Dr. Cho received her undergraduate education at Yonsei University and master degree at Korean Advanced Institute for Science and Technology. She received her doctoral degree in the field of Molecular Biology and Biochemistry from the University of Medicine and Dentistry of New Jersey, where she studied how transcriptional activation is regulated using molecular, biochemical and genetic approaches. Prior to joining Pfizer, she did her postdoctoral training at the Salk Institute for Biological Studies, studying co-regulators that govern hormone dependent transcription through epigenetic pathways in the area of chronic inflammation, metabolism and cancer. She initially came to Pfizer to find a treatment for Type II diabetes targeting chronic inflammatory pathways, but in 2007, moved to Vaccine Immunotherapeutics in order to apply her multi-disciplinary knowledge in developing a multi-modality immunotherapy regimen for cancer.

 Vaccine Immunotherapeutics and Western Oncolytics